Siemens A J
Hum Reprod. 1986 Sep;1(6):405-10. doi: 10.1093/oxfordjournals.humrep.a136436.
The clinical evaluation of drugs used in fertility regulation is initially assessed in Phase I, II and III trials. The design of each phase and the investigative staff must be adequate. In Phase I, normal, healthy human volunteers meeting specific guidelines are usually studied. Numbers vary between 20 and 80 and the purpose is to determine the acute toxicity of the compound. In Phase II, efficacy and safety are examined in a clinical target population, and emphasis may be placed on pharmacological and mechanistic studies. Usually between 50 and 200 patients are involved. In Phase III, large-scale clinical studies for local registration and the introduction of drugs to various countries are included. This paper describes the evaluation of various drugs used in contraception, including NORPLANT implants, and considers the efficiency, safety and acceptability of such drugs. Phase IV studies are usually needed to reveal chronic toxicities or rare events.
用于生育调节的药物的临床评估最初在I期、II期和III期试验中进行。每个阶段的设计和研究人员必须足够。在I期,通常研究符合特定指南的正常、健康人类志愿者。人数在20至80人之间,目的是确定该化合物的急性毒性。在II期,在临床目标人群中检查疗效和安全性,并可能侧重于药理学和机制研究。通常涉及50至200名患者。在III期,包括用于本地注册和将药物引入各个国家的大规模临床研究。本文描述了包括皮下埋植剂在内的各种避孕药物的评估,并考虑了此类药物的有效性、安全性和可接受性。通常需要进行IV期研究以揭示慢性毒性或罕见事件。